NCT05693142Phase 2, phase 3Active not recruiting

AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)

Study sponsor: REGENXBIO Inc. · RGNX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-09Estimated
Enrollment · participants65Estimated
Source updated2026-07-21Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Primary completion date changed

Before: Aug 2026. After: Sep 2026.

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

· 1 field changed

Primary completion date changed

Before: Feb 2026. After: Aug 2026.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview